Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.syngeneintl.com | |
Market Cap | 27,118.92 Cr. | |
Enterprise Value(EV) | 26,697.12 Cr. | 2024-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 12.67 | Trailing Twelve Months Ending 2024-03 |
Price-Earning Ratio (PE) | 53.17 | Trailing Twelve Months Ending 2024-03 |
Industry PE | 42.26 | Trailing Twelve Months Ending 2024-03 |
Book Value / Share | 105.79 | Trailing Twelve Months Ending 2024-03 |
Price to Book Value | 6.37 | Calculated using Price: 673.70 |
Dividend Yield | 0.19 | Period Ending 2023-03 |
No. of Shares Subscribed | 40.25 Cr. | 402,536,981 Shares |
FaceValue | 10 | |
About Syngene International Ltd. | ||
The company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Services offered by the company are Discovery Chemistry, Discovery Biology, Safety Assessment, Large Molecule Development, Chemical Development, Formulation Development, Stability Studies, Polymer Research, Integrated Discovery & Development, Clinical Development Services, Bioinformatics, Antibody Drug Conjugates, Oligonucleotide Synthesis. |
1 Day |
|
-0.84% |
1 Week |
|
-3.62% |
1 Month |
|
-6.57% |
3 Month |
|
-9.45% |
6 Month |
|
-2.78% |
1 Year |
|
-2.36% |
2 Year |
|
+8.65% |
5 Year |
|
+124.17% |
10 Year |
|
6 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 18.05 | 18.26 | 20.21 | 16.59 | 13.29 | 13.73 | |
Return on Capital Employed (%) | 15.76 | 16.98 | 19.6 | 15.4 | 13.24 | 15.43 | |
Return on Assets (%) | 9.8 | 9.86 | 10.77 | 9.17 | 7.69 | 8.25 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2024-03* Rs. Cr. |
Shh. Funds | 1,720 | 1,968 | 2,176 | 2,821 | 3,298 | 3,618 | 4,258 | |
Non Curr. Liab. | 613 | 515 | 325 | 840 | 972 | 955 | 709 | |
Curr. Liab. | 784 | 1,129 | 1,539 | 1,133 | 1,229 | 1,188 | 1,144 | |
Minority Int. | ||||||||
Equity & Liab. | 3,117 | 3,612 | 4,040 | 4,794 | 5,498 | 5,761 | 6,111 | |
Non Curr. Assets | 1,396 | 1,848 | 2,428 | 2,987 | 3,292 | 3,336 | 4,152 | |
Curr. Assets | 1,720 | 1,764 | 1,613 | 1,807 | 2,206 | 2,425 | 1,959 | |
Misc. Exp. not W/O | ||||||||
Total Assets | 3,117 | 3,612 | 4,040 | 4,794 | 5,498 | 5,761 | 6,111 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2024-03 Rs. Cr. TTM |
Net Sales | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | |
Other Income | 136 | 76 | 96 | 83 | 108 | 73 | 91 | |
Total Income | 1,559 | 1,902 | 2,108 | 2,268 | 2,713 | 3,266 | 3,579 | |
Total Expenditure | -1,033 | -1,290 | -1,409 | -1,531 | -1,864 | -2,260 | -2,474 | |
PBIDT | 527 | 612 | 700 | 736 | 849 | 1,005 | 1,105 | |
Interest | -23 | -32 | -35 | -28 | -24 | -45 | -47 | |
Depreciation | -131 | -164 | -219 | -275 | -310 | -367 | -426 | |
Taxation | -67 | -84 | -105 | -64 | -89 | -129 | -111 | |
Exceptional Items | 71 | 35 | -31 | -11 | ||||
PAT | 305 | 332 | 412 | 405 | 396 | 464 | 510 | |
Minority Interest | ||||||||
Share Associate | ||||||||
Other Related Items | ||||||||
Consolidated Net Profit | 305 | 332 | 412 | 405 | 396 | 464 | 510 | |
Adjusted EPS | 8 | 8 | 10 | 10 | 10 | 12 | 13 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 446 | 630 | 677 | 701 | 581 | 824 | |
Cash Fr. Inv. | -349 | -647 | -428 | -628 | -612 | -656 | |
Cash Fr. Finan. | -79 | -72 | -226 | 58 | -31 | -343 | |
Net Change | 18 | -89 | 23 | 131 | -62 | -175 | |
Cash & Cash Eqvt | 253 | 165 | 193 | 323 | 262 | 90 |
Mon, 29 Apr 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) please find the link for the transcript of the Q4 FY24 Earnings Call conducted on April 25 2024 and uploaded on the website of the Company on April 29 2024. |
Sun, 28 Apr 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Intimation regarding submission of appeal to the National Faceless Appeal Centre against Order under Section 143(3) read with Section 144B of the Income Tax Act 1961 |
Fri, 26 Apr 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication - Financial results. |
Mon, 06 May 2024 |
Close Within 52 Week Low Zone |
High Decrease in 1 Month |
High Decrease in 3 Months |
High Increase in 5 Years |
MFI Crossed 20 From Above |